米哚妥林塑造FLT3突变急性髓系白血病的宏克隆与微克隆演化
该回顾性多中心研究纳入150例FLT3突变复发/难治急性髓系白血病患者,比较强化化疗联合或不联合米哚妥林对FLT3克隆演化的影响。结果显示联合米哚妥林组复发/难治时FLT3-ITD持续率低于未用米哚妥林组(68% vs 87.5%,P=0.011),且多克隆检出与更高持续率相关。
要点
- 复发/难治时FLT3-ITD持续率:化疗+米哚妥林组68% vs 未用米哚妥林组87.5%(P=0.011)。
- 化疗+米哚妥林组中,多克隆检出者复发/难治时FLT3-ITD持续率88% vs 单克隆者57%(P=0.049)。
- 诊断时检出的FLT3-ITD微克隆仅24%在复发时保留,其中43%转变为宏克隆。
核心结论
- 在FLT3突变急性髓系白血病中,米哚妥林联合强化化疗较未用米哚妥林者降低复发/难治时FLT3-ITD持续率。
- 联合米哚妥林治疗时,检出多个FLT3-ITD克隆与更高的复发/难治时FLT3-ITD持续率相关。
- 部分诊断时的FLT3-ITD微克隆在复发时可转变为宏克隆。
研究设计与样本
- 回顾性多中心研究,纳入150例复发/难治FLT3突变急性髓系白血病患者。
- 诊断时FLT3-ITD阳性130例,FLT3-酪氨酸激酶结构域突变阳性26例(部分重叠)。
- 患者按诊断日期及米哚妥林上市标签接受强化化疗+米哚妥林(54例)或单纯强化化疗(96例)。
- 采用靶向高通量测序分析配对诊断-复发/难治样本中FLT3克隆及共突变演化。
主要发现
- 诊断和复发/难治两个时间点共检出189个FLT3-ITD微克隆(等位基因比值<0.05)和225个宏克隆(等位基因比值≥0.05)。
- 复发/难治时FLT3-ITD持续率:化疗+米哚妥林组68% vs 未用米哚妥林组87.5%(P=0.011)。
- 化疗+米哚妥林组中,多克隆检出者复发/难治时FLT3-ITD持续率88% vs 单克隆者57%(P=0.049)。
- 诊断时检出的FLT3-ITD微克隆仅24%在复发时保留,其中43%转变为宏克隆。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), complete remission rates are close to 60% to 70%, and relapses occur in >40% of cases. Here, we studied the molecular mechanisms underlying refractory/relapsed (R/R) disease in patients with FLT3-mutated AML. We conducted a retrospective and multicenter study involving 150 patients with R/R AML harboring FLT3-internal tandem duplication (ITD) (n = 130) and/or FLT3-tyrosine kinase domain mutation (n = 26) at diagnosis assessed by standard methods. Patients were treated with ICT + MIDO (n = 54) or ICT alone (n = 96) according to the diagnosis date and label of MIDO. The evolution of FLT3 clones and comutations was analyzed in paired diagnosis-R/R samples by targeted high-throughput sequencing. Using a dedicated algorithm for FLT3-ITD detection, 189 FLT3-ITD microclones (allelic ratio [AR] of <0.05) and 225 macroclones (AR ≥ 0.05) were detected at both time points. At R/R disease, the rate of FLT3-ITD persistence was lower in patients treated with ICT + MIDO than in patients not receiving MIDO (68% vs 87.5%; P = .011). In patients receiving ICT + MIDO, detection of multiple FLT3-ITD clones was associated with a higher FLT3-ITD persistence rate at R/R disease (multiple clones: 88% vs single clones: 57%; P = .049). If only 24% of FLT3-ITD microclones detected at diagnosis were retained at relapse, 43% became macroclones. Together, these results identify parameters influencing the fitness of FLT3-ITD clones.
引用
- Joudinaud R, Boudry A, Fenwarth L, et al. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia. Blood Adv. 2025. PMID: 39418643. doi:10.1182/bloodadvances.2024014672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。